Summary of Variables Across Groups of Response to Dopaminergic Treatment
| Treatment response category | Dichotomized response | ||||||||
| Variable | Group | 0 | 1 | 2 | 3 | P | Nonresponder | Responder | P |
| All | 0.47 ± 0.08a | 0.48 ± 0.08b | 0.50 ± 0.10c | 0.62 ± 0.07a–c | <0.001 | 0.47 ± 0.08 | 0.55 ± 0.11 | 0.002 | |
| D2R binding (BPND) | LBD | (0.63, 0.50) | 0.49 ± 0.05 | 0.51 ± 0.13 | 0.62 ± 0.07 | 0.041 | 0.52 ± 0.07 | 0.57 ± 0.11 | 0.265 |
| APS | 0.46 ± 0.08 | 0.47 ± 0.10 | 0.48 ± 0.05 | — | 0.840 | 0.46 ± 0.08 | 0.48 ± 0.05 | 0.592 | |
| Diagnosis | LBD/APS | 2/17 | 4/9 | 9/6 | 13/0 | <0.001 | 6/26 | 22/6 | <0.001 |
| All | 65.3 ± 9.2 | 70.8 ± 8.4d | 68.0 ± 11.8 | 57.7 ± 13.0d | 0.017 | 67.5 ± 9.2 | 63.2 ± 13.2 | 0.153 | |
| Age (y) | LBD | (47, 68) | 75.0 ± 3.4 | 66.8 ± 14.6 | 57.7 ± 13.0 | 0.105 | 69.1 ± 11.5 | 61.4 ± 14.1 | 0.232 |
| APS | 66.2 ± 8.6 | 68.9 ± 9.4 | 69.7 ± 6.6 | — | 0.604 | 67.1 ± 8.8 | 69.7 ± 6.6 | 0.510 | |
| All | 3.7 ± 1.7 | 3.9 ± 2.5 | 3.8 ± 2.7 | 3.2 ± 1.9 | 0.874 | 3.8 ± 2.0 | 3.5 ± 2.3 | 0.695 | |
| Duration (y) | LBD | (3.8, 3.8) | 4.4 ± 3.4 | 4.8 ± 3.1 | 3.2 ± 1.9 | 0.565 | 4.2 ± 2.7 | 3.9 ± 2.5 | 0.780 |
| APS | 3.7 ± 1.8 | 3.6 ± 2.2 | 2.4 ± 1.3 | — | 0.335 | 3.7 ± 1.9 | 2.4 ± 1.3 | 0.136 | |
| All | 3.5 ± 0.9e | 3.8 ± 1.1f | 3.2 ± 1.1g | 2.1 ± 0.8e–g | <0.001 | 3.6 ± 1 | 2.7 ± 1.1 | 0.001 | |
| H&Y stage | LBD | (3, 2.5) | 4.1 ± 1.2 | 2.9 ± 1.3 | 2.1 ± 0.8 | 0.074 | 3.7 ± 1.2 | 2.4 ± 1.1 | 0.049 |
| APS | 3.6 ± 1.0 | 3.7 ± 1.1 | 3.7 ± 0.5 | — | 0.866 | 3.6 ± 1 | 3.7 ± 0.5 | 0.806 | |
Groups connected by same letters are significantly different (a–f) or show trend effect (g; P = 0.054) on post hoc testing. Qualitative data are expressed as numbers; continuous data are expressed as mean ± SD. Numbers in parentheses indicate raw individual values.